Tirzepatide for diabetes: on track to SURPASS current therapy

Nat Med. 2022 Mar;28(3):450-451. doi: 10.1038/s41591-022-01733-2.

Authors

Filipe A Moura¹, Benjamin M Scirica¹, Christian T Ruff²

Affiliations

¹ TIMI Study Group, Division of Cardiovascular Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
² TIMI Study Group, Division of Cardiovascular Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA. cruff@bwh.harvard.edu.

PMID: 35260841
DOI: 10.1038/s41591-022-01733-2

No abstract available

Publication types

Comment

MeSH terms

Cardiovascular Diseases*
Diabetes Mellitus* / drug therapy
Gastric Inhibitory Polypeptide
Humans
Hypoglycemic Agents / therapeutic use

Substances

Hypoglycemic Agents
Gastric Inhibitory Polypeptide
tirzepatide